You are here:

co-careldopa (Duodopa)

Advice

following a resubmission considered under the orphan process

co-careldopa (Duodopa®) intestinal gel is not recommended for use within NHS Scotland.

Indication under review: treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.

In a phase III, 12-week study, co-careldopa intestinal gel significantly reduced ‘off’ time compared with oral levodopa plus a dopa decarboxylase inhibitor. 

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: co-careldopa (Duodopa)
SMC Drug ID: 316/06
Manufacturer: AbbVie Ltd
Indication: treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 7 December 2015

Archived Advice

Full submission 9 October 2006

Back